Meeder Asset Management Inc Protagonist Therapeutics, Inc Transaction History

Meeder Asset Management Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 11, 2020	SELL	$6.19 - $18.84 $2,469 - $7,517	-399 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$5.4 - $9.22 $4,379 - $7,477	-811 Reduced 67.02%	399 $3,000
Q4 2019 Feb 13, 2020	SELL	$4.69 - $13.45 $10,505 - $30,128	-2,240 Reduced 64.93%	1,210 $9,000
Q3 2019 Oct 17, 2019	BUY	$9.41 - $16.56 $30,347 - $53,405	3,225 Added 1433.33%	3,450 $41,000
Q2 2019 Aug 05, 2019	SELL	$8.98 - $12.96 $3,762 - $5,430	-419 Reduced 65.06%	225 $3,000
Q1 2019 Apr 16, 2019	SELL	$6.5 - $13.77 $1,774 - $3,759	-273 Reduced 29.77%	644 $8,000
Q4 2018 Jan 17, 2019	BUY	$6.3 - $10.44 $705 - $1,169	112 Added 13.91%	917 $6,000
Q3 2018 Nov 02, 2018	BUY	$6.82 - $11.26 $3,682 - $6,080	540 Added 203.77%	805 $0
Q2 2018 Jul 24, 2018	SELL	$5.99 - $9.1 $467 - $709	-78 Reduced 22.74%	265 $0
Q1 2018 May 03, 2018	SELL	$8.46 - $23.08 $490 - $1,338	-58 Reduced 14.46%	343 $2,000
Q4 2017 Feb 02, 2018	BUY	$14.47 - $20.8 $5,802 - $8,340	401	401 $8,000

248

56.7M

76.3K

114K

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $1.93B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Meeder Asset Management Inc with notifications on news.